Wedbush Rates Viridian Therapeutics (VRDN) buy, $43 Price Target

A wave of analyst optimism follows recent pipeline progress for the biotechnology firm specializing in rare diseases, a 134.08% upside from the current price.

By TradeTexts Research Desk · Published Jul 1, 2026, 3:02 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wedbush rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $43 price target on June 30, 2026.

Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).

VRDN Viridian Therapeutics, Inc.

$19.03 -37.97% year to date

Daily close · Oct 16, 2026

Key Points

Analyst Laura Chico of Wedbush reaffirmed a buy rating for Viridian Therapeutics on June 30, 2026, setting a price target of $43.00.
Wedbush's $43 price target implies 134.08% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.37 share price.
The stock was trading at $18.37 on Wednesday, sitting well below its 200-day moving average of $23.36 and its 52-week high of $34.29.
Viridian reported $71.13 million in revenue and a 2.787% growth rate, though it remains in a development phase with negative earnings per share of $3.40.

Get $VRDN trade alerts by text

We text you when insiders, Congress or big funds trade $VRDN. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures

On June 30, 2026, Wedbush analyst Laura Chico reiterated a buy rating on Viridian Therapeutics, Inc. (VRDN) with a price target of $43.00. The stock, which trades on the Nasdaq Capital Market, was priced at $18.37 on Wednesday. This price target suggests the firm sees substantial room for the stock to rise from its current levels as the company advances its clinical programs.

Analyst rating track record

Wedbush vs. the S&P 500

YTD return +10.53% hypothetical

All-time return +13.17% S&P 500 +43.35%

vs. S&P 500 -30.18% behind the index

Hypothetical returns from Wedbush's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

Several other investment firms adjusted their outlooks on the same day as the Wedbush report. On June 30, 2026, Truist Securities maintained its buy rating and lifted its target to $38.00 from $35.00. Needham also kept a buy rating, raising its price target to $34.00 from $32.00. RBC Capital joined the trend by maintaining an outperform rating and nudging its target up to $35.00. More recently, on September 22, 2026, RBC Capital boosted its target again to $38.00. The consensus among 16 analysts is generally positive, with a mean price target of $36.63.

Viridian Stock Performance and Valuation

Viridian shares have faced some pressure recently, trading at $18.37. This is lower than the 50-day moving average of $21.66 and the 200-day moving average of $23.36. Over the last year, the stock has fluctuated between a low of $13.18 and a high of $34.29. With a market capitalization of about $2.44 billion, the company currently has no meaningful P/E ratio because it is not profitable. However, its current ratio of 16.95 and quick ratio of 16.56 indicate a very strong cash position relative to its short-term debts.

12-month forecast

$VRDN price target

Viridian Therapeutics, Inc. daily closes and this analyst's $43 target. Not advice.

Recent Earnings and Financial Health

In its most recent financial reporting, Viridian posted revenue of $71.13 million, which represents a growth rate of 2.787%. The company reported a loss of $3.40 per share, which is common for biotechnology firms that are still testing new drugs. Its return on equity stands at -0.65. Investors are looking ahead to the next earnings date, which is scheduled for November 5, 2026, to see if the company can maintain its revenue trajectory and manage its research costs.

Rare Disease Drug Development

Viridian Therapeutics is a Waltham, Massachusetts-based biotech firm that focuses on treatments for serious and rare conditions. Its main projects include Veligrotrug and Elegrobart, which are being developed to treat thyroid eye disease. The company is also working on treatments for Graves' disease. The bullishness from analysts often stems from the potential for these therapies to reach the market and provide new options for patients who have few alternatives.

Looking Toward the Future

Market watchers will likely focus on clinical trial updates and the upcoming November earnings report to see if the company's financial results match the optimistic targets set by Wall Street. While the $43.00 target from Wedbush is much higher than the current share price, it is important to remember that analyst ratings are opinions and 13F filings or research reports are based on data available at the time of the report. Future stock performance will depend on the success of Viridian's drug pipeline and broader market conditions.